Belizatinib

N/A

Report date: 2023/06/01 20:00:46
NME

Base Information

Drug NameBelizatinib
Drug Alias NameTSR-011
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNerve growth factor receptor Trk-A antagonistsAnaplastic lymphoma kinase inhibitors
TargetsNerve growth factor receptor Trk-AAnaplastic lymphoma kinase
Therapy Area/IndicationsSolid tumoursLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanPoland +[5] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTesaro Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursLymphoma

Other Information

ATC CodeN/A
Related LinksN/A